Search hospitals
>
Illinois
>
Pekin
Illinois CancerCare-Pekin
Claim this profile
Pekin, Illinois 61554
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
478 reported clinical trials
2 medical researchers
Summary
Illinois CancerCare-Pekin is a medical facility located in Pekin, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Pekin is involved with conducting 478 clinical trials across 495 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.
Area of expertise
Breast Cancer
Illinois CancerCare-Pekin has run 92 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Illinois CancerCare-Pekin has run 83 trials for Lung Cancer. Some of their research focus areas include:
Top PIs
Bryan A. Faller
Crossroads Cancer Center
7 years of reported clinical research
James L. Wade
Decatur Memorial Hospital
4 years of reported clinical research
Clinical Trials running at Illinois CancerCare-Pekin
Lung Cancer
Prostate Cancer
Breast Cancer
Pancreatic Cancer
Bladder Cancer
Cancer
Breast cancer
Colorectal Cancer
Ovarian Cancer
Non-Small Cell Lung Cancer
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting
2 awards
Phase 3
4 criteria
Ceralasertib + Durvalumab
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Recruiting
2 awards
Phase 3
10 criteria
High-Dose Radiation + Chemotherapy and Immunotherapy
for Non-Small Cell Lung Cancer
This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.
Recruiting
2 awards
Phase 3
14 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Illinois CancerCare-Pekin?
Illinois CancerCare-Pekin is a medical facility located in Pekin, Illinois. This center is recognized for care of Breast Cancer, Lung Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Illinois CancerCare-Pekin is involved with conducting 478 clinical trials across 495 conditions. There are 2 research doctors associated with this hospital, such as Bryan A. Faller and James L. Wade.
Where is Illinois CancerCare-Pekin located?
Illinois CancerCare-Pekin is located at 1641 Broadway Street, Pekin, IL 61554. This hospital is currently accepting new patients and provides a range of cancer treatments.
Who should I call to ask about financial aid or insurance network?
**Illinois CancerCare-Pekin Contact Information:** - **Financial Assistance:** Reach out to the Patient Financial Counselor for assistance with insurance benefits, foundation applications, grants, and managing out-of-pocket expenses. Contact at (309) 243-3500 or toll-free (866) 662-6564. - **Insurance and Billing Inquiries:** Contact the Illinois CancerCare Business Office for insurance claims, pre-certifications, and understanding insurance coverage and financial responsibilities. Call (309) 243-3500 or toll-free (866) 662-6564. - **General Inquiries:** For any other questions, call the Illinois CancerCare-Pekin location at (309) 243-3500.
What insurance does Illinois CancerCare-Pekin accept?
Illinois CancerCare-Pekin accepts a wide range of insurance plans, including but not limited to Medicare, Aetna (HMO, PPO, POS), BCBS of Illinois (PPO, POS, EPO, Classic Blue HMO, HMOI, Blue Advantage HMO), Beech Street PPO, Cigna/Great West Healthcare (HMO, PPO, POS, Open Access), and United Health Care. Other accepted insurances include Coventry/First Health/Personal Care, Humana (HMO, PPO, Choice POS, Choice Care Network), and Multiplan. Patients are advised to verify physician participation in their plan and discuss any necessary pre-certification with the office.
What awards or recognition has Illinois CancerCare-Pekin received?
Illinois CancerCare-Pekin, located in Pekin, Illinois, is distinguished by the Quality Oncology Practice Initiative (QOPI®) Certification Program for its outstanding outpatient hematology-oncology practices. It was honored in 2015 by the Alliance for Clinical Trials in Oncology as a leading institution in clinical research enrollment. Additionally, it received the 2007 Clinical Trials Participation Award from the American Society of Clinical Oncology for its significant contributions to advancing cancer treatments through clinical trials.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.